Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23057886 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ESR1HSD17B10ACP3 | |
| SCHEMBL28970482 | 0.83 | ALDH1A1 (0.44) | ALDH1A1CYP3A4ESR1HSD17B10ACP3 | |
| SCHEMBL9445842 | 0.81 | LMNA (0.45) | ALDH1A1ESR1ACP3PPARAL3MBTL1 | |
| SCHEMBL9445841 | 0.81 | LMNA (0.45) | ALDH1A1ESR1ACP3PPARAL3MBTL1 | |
| SCHEMBL9445845 | 0.81 | LMNA (0.45) | ALDH1A1ESR1ACP3PPARAL3MBTL1 | |
| SCHEMBL19451943 | 0.81 | TSHR (0.48) | ALDH1A1CYP3A4HSD17B10ACP3TSHR | |
| SCHEMBL8069967 | 0.81 | TSHR (0.48) | ALDH1A1CYP3A4HSD17B10ACP3TSHR | |
| SCHEMBL10369275 | 0.81 | KMT2A (0.49) | ALDH1A1CYP3A4HSD17B10HPGDKMT2A | |
| SCHEMBL9446766 | 0.81 | MEN1 (0.57) | ALDH1A1CYP3A4HSD17B10TSHRMEN1 | |
| SCHEMBL29845650 | 0.81 | TSHR (0.48) | ALDH1A1CYP3A4HSD17B10ACP3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331054-B2 | Perk inhibiting imidazolopyrazine compounds | HIBERCELL, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220348583-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | EEF2K, ATF4, MAPKAPK2 | ALDH1A1 2477/4885CYP3A4 3991/4885ESR1 1233/4885 |
| US-20220348583-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | MAPKAPK2, MAPK4, MAP3K5 | ALDH1A1 2619/4885CYP3A4 3599/4885ESR1 955/4885 |
| US-12331054-B2 | Perk inhibiting imidazolopyrazine compounds | MAPKAPK2, MAPK4, MAP3K5 | ALDH1A1 2619/4885CYP3A4 3599/4885ESR1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.